Ivermectin is one of the more remarkable drugs in modern medicine's cabinet, and also one of the most misunderstood. This article lays out plainly what it is, how it works, which infections it is actually approved to treat, how the brand-name product Stromectol differs from the generic tablets that now dominate the market, what legitimate alternatives exist, and what the actual clinical trial evidence says about uses beyond its approved indications. The goal is understanding, not persuasion in either direction.
A Medicine Born From the Soil
Ivermectin descends from avermectin, a compound isolated from Streptomyces avermitilis, a bacterium found in a soil sample collected in Japan and cultured by microbiologist Satoshi Ōmura. Working with parasitologist William Campbell at Merck, researchers found that a derivative of this soil organism's natural chemistry was extraordinarily effective against parasitic worms in animals, and later in humans. Ōmura and Campbell shared the 2015 Nobel Prize in Physiology or Medicine for this work. It is worth pausing on that origin: a compound quietly produced by an ordinary microbe in ordinary dirt has, since the 1980s, spared an enormous number of people from blindness and disfiguring disease. There is something fitting in that — real medical progress often comes not from inventing something new out of nothing, but from noticing what has been provided and learning to use it well.
How Ivermectin Actually Works
Ivermectin binds selectively to glutamate-gated chloride channels found in the nerve and muscle cells of nematodes (roundworms) and certain arthropods. This binding opens the channel, chloride ions flood in, the parasite's nerve and muscle cells become hyperpolarized, and the parasite is paralyzed and dies. Mammals, including humans, do not have this particular type of glutamate-gated channel; our chloride channels are gated differently. Ivermectin does have some affinity for the GABA-gated channels mammals use in the central nervous system, but two safeguards keep it from causing the same effect in people at normal doses: those receptors are mostly confined to the brain and spinal cord, and the blood-brain barrier, along with a transport protein called P-glycoprotein, actively keeps ivermectin out of the central nervous system. This is why certain dog breeds with a genetic mutation affecting that transport protein (collies, in particular) can suffer severe neurological toxicity from ivermectin doses that other dogs tolerate easily — a useful illustration of just how much of the drug's safety margin depends on a barrier working as designed.
What Ivermectin Is Approved to Treat — and What It Is Not
In the United States, oral ivermectin tablets are FDA-approved for two conditions:
- Intestinal strongyloidiasis, an infection with the roundworm Strongyloides stercoralis
- Onchocerciasis, or river blindness, caused by the filarial worm Onchocerca volvulus
Topical formulations have separate approvals: a 0.5% lotion for head lice and a 1% cream for the inflammatory skin condition rosacea. Beyond these labeled uses, ivermectin is prescribed off-label, with support from CDC and WHO guidance, for scabies (particularly crusted scabies and institutional outbreaks) and as part of mass drug administration campaigns for lymphatic filariasis, usually alongside albendazole or diethylcarbamazine. "Off-label" simply means a use is not written into the FDA-approved label, not that it lacks evidence — but it does mean the evidence base and dosing conventions rest more on clinical experience and international guidelines than on a formal U.S. approval process. It is not approved, in the United States or elsewhere, as a treatment for COVID-19, and that distinction matters enough to address in its own right further down.
Brand-Name Stromectol Versus Generic Ivermectin
Stromectol was the original branded oral ivermectin product, approved by the FDA in 1996. Its patent has long since expired, and the overwhelming majority of ivermectin dispensed in the U.S. today is generic. By law, a generic must contain the identical active ingredient at the identical dose and must demonstrate bioequivalence — meaning its rate and extent of absorption into the bloodstream fall within a tightly defined range (generally 80–125%) of the brand product's. In practice, this means a generic 3 mg ivermectin tablet works the same way in the body as the branded equivalent. What can differ are the inactive ingredients — fillers, binders, coatings, dyes — which occasionally matter for someone with a specific excipient sensitivity, but not for the drug's core action.
Where confusion often arises is around tablet strength. The FDA-approved oral tablet in the U.S. is 3 mg; doses are calculated by body weight and reached by combining tablets. Products labeled 6 mg or 12 mg are manufactured and sold mainly outside the U.S., notably in India, and became widely discussed during the pandemic. These are not FDA-approved formulations, and buying them through unregulated online pharmacies carries real risks around dosing accuracy, contamination, and counterfeiting that a licensed U.S. pharmacy does not carry. Separately, the FDA has repeatedly warned against using veterinary ivermectin — pastes and injectable formulations made for livestock — in humans; these are dosed and formulated for animals many times a person's size and are not held to human pharmaceutical standards. Anyone considering ivermectin for a legitimate indication should obtain it from a licensed pharmacy under a physician's guidance, which is simply sound stewardship of one's own health.
When Doctors Reach for Something Else: Alternatives
Ivermectin is not the only, or always the best, option for the conditions it treats:
- Onchocerciasis: Moxidectin, approved by the FDA in 2018 for patients 12 and older, is a related but longer-acting drug developed through a partnership including Medicines Development for Global Health and supported by WHO. A published phase 3 trial found moxidectin produced a more sustained reduction in skin microfilariae than ivermectin over 12 months, though ivermectin remains the mainstay in most mass treatment programs due to decades of established use and safety data.
- Scabies: Topical permethrin 5% cream is the standard first-line treatment recommended by the CDC. Oral ivermectin is generally reserved for crusted scabies, treatment failures, or outbreak settings such as nursing homes, where topical application to every resident is impractical.
- Strongyloidiasis: Albendazole is an alternative, but comparative studies have generally shown lower cure rates than ivermectin, which is why ivermectin is preferred where available.
- Lymphatic filariasis: In regions where the filarial parasite Loa loa is also common, mainly parts of Central Africa, ivermectin can trigger severe, sometimes fatal, encephalopathic reactions in people with high Loa loa microfilarial loads. Programs in those areas use screening protocols or substitute diethylcarbamazine and albendazole instead. This is a genuine, well-documented safety limitation, not a theoretical one, and it is a good example of why weight-based, physician-supervised dosing and proper screening matter more than the drug's reputation for being simple and safe in general.
The COVID-19 Question
Because this comes up so often, it deserves a direct answer grounded in the evidence rather than in either dismissal or hope. Early laboratory research, including a widely cited 2020 study from Monash University in Australia published in Antiviral Research, found that ivermectin could inhibit SARS-CoV-2 replication in cell culture. That finding generated understandable interest, but the concentrations required to achieve that effect in a test tube were far higher than what is safely achievable in human blood at approved oral doses — a gap that later pharmacokinetic analyses confirmed. Since then, large, well-designed randomized controlled trials have tested the question directly in people. The NIH-funded ACTIV-6 platform trial, published in JAMA in 2022, found no significant improvement in recovery time among outpatients with mild-to-moderate COVID-19 given ivermectin versus placebo. The TOGETHER trial, an adaptive platform trial run in Brazil and Canada and published in the New England Journal of Medicine in 2022, similarly found ivermectin did not reduce the risk of hospitalization in high-risk outpatients compared with placebo. Based on this body of evidence, the FDA has not authorized or approved ivermectin for COVID-19, and current NIH treatment guidelines do not recommend it for that purpose outside a research setting. None of this diminishes ivermectin's genuine, well-established value against the parasitic diseases it was built to fight — it simply means the evidence does not support this particular additional use, and saying so plainly is more respectful of readers than leaving the question vague.
Key takeaway: Ivermectin is a genuinely valuable, well-studied antiparasitic medicine when used for its approved and evidence-supported indications, generic versions are pharmacologically equivalent to the branded original, and any decision to use it — including for off-label purposes — belongs in an honest conversation with your own physician, grounded in the actual evidence rather than in rumor in either direction.